May 15, 2018 – 8:20am

The Council of Canadians has been highlighting the threat posed to winning pharmacare by so-called ‘free trade’ agreements.

A study by Joel Lexchin (York University) and Marc-André Gagnon (Carleton University) found that the extended patent provisions for pharmaceutical drugs under the Canada-European Union Comprehensive Economic and Trade Agreement (CETA) could cost between $850 million to $1.65 billion annually.

And Steve Morgan (University of British Columbia) and…